Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Automated synthesis of Ga-68/Lu-177-PSMA on the Trasis miniAllinOne

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Radiosynthesis and preclinical evaluation of [C-11]Cimbi-701-Towards the imaging of cerebral 5-HT7 receptors

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Evaluation of [18 F]2FP3 in pigs and non-human primates

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. (99m)Tc-aprotinin - optimisation and validation of radiolabelling kits for routine preparation for diagnostic imaging of amyloidosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Factors associated with melanoma-related limb lymphoedema

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Observer Agreement and Accuracy of F-18-Sodium Fluoride PET/CT in the Diagnosis of Bone Metastases in Prostate Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Prostate-specific membrane antigen (PSMA)-based radioligands for positron emission tomography (PET)/computed tomography (CT) studies represent the gold standard for detection of recurrent prostate cancer (PCa). [ 68Ga]PSMA-HBED-CC is a PET radiotracer suitable for detection of PCa, and its clinical use has become widespread over the last few years. In this contribution, we detail our GMP-compliant production of [ 68Ga]PSMA-HBED-CC using the Trasis miniAllinOne radiosynthesizer and report synthetic and clinical data for the first 100 productions of 2019. Additionally, we detail our efforts towards a GMP-compliant production of the radiotherapeutic [ 177Lu]PSMA-I&T using the same synthesis module. PSMA-based radioligand therapy (RLT) offers a possible future treatment in cases of metastatic castration-resistant PCa, and GMP-compliant routine production methods are therefore called for. This report highlights how PSMA-based agents for theranostic purposes can be conveniently produced at a single radiochemistry Good Manufacturing Practice (GMP) site, thereby facilitating optimized detection and treatment of PCa.

Original languageEnglish
JournalJournal of Labelled Compounds and Radiopharmaceuticals
Volume63
Issue number8
Pages (from-to)393-403
Number of pages11
ISSN0362-4803
DOIs
Publication statusPublished - 30 Jun 2020

Bibliographical note

© 2020 John Wiley & Sons, Ltd.

    Research areas

  • GMP, PET/CT, prostate cancer, PSMA, [ Lu]PSMA-I&T, [ Ga]PSMA-HBED-CC

ID: 59823483